NasdaqGM - Nasdaq Real Time Price USD

ADMA Biologics, Inc. (ADMA)

6.58 +0.14 (+2.17%)
As of 2:44 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
258,215.00
258,215.00
154,080.00
80,943.00
42,219.78
Cost of Revenue
169,273.00
169,273.00
118,815.00
79,770.00
61,291.43
Gross Profit
88,942.00
88,942.00
35,265.00
1,173.00
-19,071.64
Operating Expense
67,310.00
67,310.00
74,630.00
59,547.00
45,843.23
Operating Income
21,632.00
21,632.00
-39,365.00
-58,374.00
-64,914.88
Net Non Operating Interest Income Expense
-23,410.00
-23,410.00
-19,234.00
-13,022.00
-11,696.94
Other Income Expense
-26,461.00
-26,461.00
-7,305.00
-252.00
863.27
Pretax Income
-28,239.00
-28,239.00
-65,904.00
-71,648.00
-75,748.55
Net Income Common Stockholders
-28,239.00
-28,239.00
-65,904.00
-71,648.00
-75,748.55
Diluted NI Available to Com Stockholders
-28,239.00
-28,239.00
-65,904.00
-71,648.00
-75,748.55
Basic EPS
-0.13
--
-0.33
-0.51
-0.88
Diluted EPS
-0.13
--
-0.33
-0.51
-0.88
Basic Average Shares
223,977.32
--
197,874.90
139,578.54
86,145.05
Diluted Average Shares
223,977.32
--
197,874.90
139,578.54
86,145.05
Total Operating Income as Reported
21,632.00
21,632.00
-39,365.00
-58,374.00
-64,914.88
Total Expenses
236,583.00
236,583.00
193,445.00
139,317.00
107,134.66
Net Income from Continuing & Discontinued Operation
-28,239.00
-28,239.00
-65,904.00
-71,648.00
-75,748.55
Normalized Income
-2,065.00
-2,065.00
-59,234.00
-71,648.00
-76,740.35
Interest Income
1,617.00
1,617.00
45.00
35.00
288.13
Interest Expense
25,027.00
25,027.00
19,279.00
13,057.00
11,985.07
Net Interest Income
-23,410.00
-23,410.00
-19,234.00
-13,022.00
-11,696.94
EBIT
-3,212.00
-3,212.00
-46,625.00
-58,591.00
-63,763.48
EBITDA
5,120.00
5,120.00
-39,512.00
-53,095.00
-59,821.19
Reconciled Cost of Revenue
161,665.00
161,665.00
112,417.00
74,989.00
58,064.49
Reconciled Depreciation
8,332.00
8,332.00
7,113.00
5,496.00
3,942.29
Net Income from Continuing Operation Net Minority Interest
-28,239.00
-28,239.00
-65,904.00
-71,648.00
-75,748.55
Total Unusual Items Excluding Goodwill
-26,174.00
-26,174.00
-6,670.00
--
991.80
Total Unusual Items
-26,174.00
-26,174.00
-6,670.00
--
991.80
Normalized EBITDA
31,294.00
31,294.00
-32,842.00
-53,095.00
-60,812.99
12/31/2020 - 10/17/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

VNDA Vanda Pharmaceuticals Inc.
4.5750
+2.12%
 
EYEN Eyenovia, Inc.
0.6090
-14.38%
 
ANNX Annexon, Inc.
4.7400
+3.27%
 
IOVA Iovance Biotherapeutics, Inc.
11.73
+1.64%
 
CDTX Cidara Therapeutics, Inc.
13.18
+1.38%
 
ALDX Aldeyra Therapeutics, Inc.
3.9440
+0.10%
 
AKBA Akebia Therapeutics, Inc.
1.3240
-0.45%
 
FGEN FibroGen, Inc.
1.0350
+1.47%
 
AXSM Axsome Therapeutics, Inc.
71.75
+0.32%
 
PBYI Puma Biotechnology, Inc.
5.00
+2.46%